Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

S&P Pharmaceuticals SPDR (XPH)

S&P Pharmaceuticals SPDR (XPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family State Street Global Advisors
  • Assets Under Management 209,078,300
  • Market Capitalization, $K 209,078
  • Shares Outstanding, K 5,050
  • 60-Month Beta 1.34
  • Price/Earnings ttm 10.33
  • Annual Dividend & Yield 0.33 (0.78%)
  • Most Recent Dividend 0.084 on 09/23/19
  • Management Fee 0.35%
  • Sectors:

    ETFs - Biotech

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.92 +10.47%
on 11/14/19
42.37 -1.13%
on 12/13/19
+3.64 (+9.52%)
since 11/13/19
3-Month
34.37 +21.88%
on 10/02/19
42.37 -1.13%
on 12/13/19
+4.58 (+12.28%)
since 09/13/19
52-Week
34.37 +21.88%
on 10/02/19
43.83 -4.43%
on 03/04/19
+0.67 (+1.63%)
since 12/13/18

Most Recent Stories

More News
Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

PPH : 63.64 (-0.29%)
XPH : 41.89 (-0.19%)
PJP : 64.42 (-0.45%)
ALXN : 110.42 (-1.82%)
BIIB : 296.83 (+1.01%)
ACHN : 6.26 (+0.81%)
DERM : 12.70 (-1.32%)
GLYC : 5.96 (-3.25%)
RIGL : 2.23 (-1.33%)
IRWD : 12.79 (+1.35%)
Pharma ETFs Set to Benefit Post Strong Q3 Earnings

Robust results led to solid trading in pharma ETFs in a month.

XPH : 41.89 (-0.19%)
PJP : 64.42 (-0.45%)
PPH : 63.64 (-0.29%)
IHE : 155.34 (+0.04%)
FTXH : 23.24 (+1.31%)
Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

Despite robust results, pharma ETFs have been trending downward in a month.

PJP : 64.42 (-0.45%)
XPH : 41.89 (-0.19%)
PPH : 63.64 (-0.29%)
IHE : 155.34 (+0.04%)
FTXH : 23.24 (+1.31%)
AbbVie to Buy Allergan: Prescribed ETFs

AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

BMY : 63.82 (-0.19%)
AGN : 188.34 (+0.04%)
ABBV : 87.84 (-1.00%)
BBH : 140.49 (+0.94%)
PPH : 63.64 (-0.29%)
XPH : 41.89 (-0.19%)
IHE : 155.34 (+0.04%)
PJP : 64.42 (-0.45%)
CELG : 108.24 (+0.10%)
Pharma ETFs Down Despite Solid Q1 Results

Despite such robust results, pharma ETFs have been trending downward in a month.

XPH : 41.89 (-0.19%)
PJP : 64.42 (-0.45%)
IHE : 155.34 (+0.04%)
PPH : 63.64 (-0.29%)
FTXH : 23.24 (+1.31%)
Pharma ETFs Down Despite Solid Q1 Results

Despite such robust results, pharma ETFs have been trending downward in a month.

XPH : 41.89 (-0.19%)
PJP : 64.42 (-0.45%)
IHE : 155.34 (+0.04%)
PPH : 63.64 (-0.29%)
FTXH : 23.24 (+1.31%)
Why These Pharma ETFs Rallied on Thursday

A few pharma ETFs hit a one-month high on Feb 28. Why?

XPH : 41.89 (-0.19%)
IHE : 155.34 (+0.04%)
PJP : 64.42 (-0.45%)
TGTX : 10.10 (+7.50%)
HZNP : 32.84 (+1.83%)
RKDA : 5.53 (+3.56%)
FTXH : 23.24 (+1.31%)
Why These Pharma ETFs Rallied on Thursday

A few pharma ETFs hit a one-month high on Feb 28. Why?

XPH : 41.89 (-0.19%)
IHE : 155.34 (+0.04%)
PJP : 64.42 (-0.45%)
TGTX : 10.10 (+7.50%)
HZNP : 32.84 (+1.83%)
RKDA : 5.53 (+3.56%)
FTXH : 23.24 (+1.31%)
A Look at Pharma ETFs Post Q4 Results

The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month.

IHE : 155.34 (+0.04%)
PPH : 63.64 (-0.29%)
PJP : 64.42 (-0.45%)
XPH : 41.89 (-0.19%)
FTXH : 23.24 (+1.31%)
A Look at Pharma ETFs Post Q4 Results

The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month.

IHE : 155.34 (+0.04%)
PPH : 63.64 (-0.29%)
PJP : 64.42 (-0.45%)
XPH : 41.89 (-0.19%)
FTXH : 23.24 (+1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade XPH with:

Fund Summary

The SPDR SP Pharmaceuticals ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the SP Pharmaceuticals Select Industry Index.

See More

Key Turning Points

2nd Resistance Point 42.65
1st Resistance Point 42.27
Last Price 41.89
1st Support Level 41.61
2nd Support Level 41.33

See More

52-Week High 43.83
Last Price 41.89
Fibonacci 61.8% 40.22
Fibonacci 50% 39.10
Fibonacci 38.2% 37.98
52-Week Low 34.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar